New cancer pill targets specific gene fault in advanced tumors

NCT ID NCT03006172

Summary

This early-stage study is testing the safety and dosing of an experimental pill called inavolisib. It is for people with advanced breast cancer or other solid tumors that have a specific genetic change called a PIK3CA mutation. The study will give the pill alone or in combination with other standard cancer medications to see how the body handles it and what side effects occur.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Hospital Clinico Universitario de Valencia

    Valencia, 46010, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035, Spain

  • Institut Bergonie

    Bordeaux, 33076, France

  • Institut Gustave Roussy

    Villejuif, 94805, France

  • Massachusetts General Hospital.

    Boston, Massachusetts, 02114, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10017, United States

  • Princess Margaret Hospital

    Toronto, Ontario, M5G2M9, Canada

  • Royal Marsden Hospital - London

    London, SW3 6JJ, United Kingdom

  • Royal Marsden Hospital - Surrey

    Surrey, Sutton, SM2 5PT, United Kingdom

  • SCRI Oncology Partners

    Nashville, Tennessee, 37203, United States

  • St Bartholomew's Hospital

    London, EC1 A7BE, United Kingdom

Conditions

Explore the condition pages connected to this study.